IL17A

Across TCGA pan-cancer cohorts, IL17A mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of IL17A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where IL17A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types IL17A is over-expressed in tumor.

HNSC, LUAD, and LSCC are the cancer types where IL17A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IL17A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.835	<.001	7	view →
LUAD	All	All	+0.620	.027	2	view →
LSCC	All	All	+0.680	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

IL17A–HNSC

Open the HNSC breakdown →